Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Shares Outstanding (Diluted Average) (2023 - 2025)

Historic Shares Outstanding (Diluted Average) for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $15.5 million.

  • Inhibrx Biosciences' Shares Outstanding (Diluted Average) rose 6.46% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 6.46%. This contributed to the annual value of $15.0 million for FY2024, which is 2716.63% up from last year.
  • Per Inhibrx Biosciences' latest filing, its Shares Outstanding (Diluted Average) stood at $15.5 million for Q3 2025, which was up 6.46% from $15.5 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Shares Outstanding (Diluted Average) high stood at $15.5 million for Q3 2025, and its period low was $10.9 million during Q2 2023.
  • For the 3-year period, Inhibrx Biosciences' Shares Outstanding (Diluted Average) averaged around $14.0 million, with its median value being $14.9 million (2024).
  • Per our database at Business Quant, Inhibrx Biosciences' Shares Outstanding (Diluted Average) surged by 3570.71% in 2024 and then grew by 6.46% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Shares Outstanding (Diluted Average) (Quarter) stood at $11.8 million in 2023, then increased by 27.17% to $15.0 million in 2024, then grew by 3.3% to $15.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $15.5 million in Q3 2025, compared to $15.5 million in Q2 2025 and $15.5 million in Q1 2025.